FDA approves 2 PARP inhibitors for certain men with prostate cancerMay 21st 2020
The FDA has approved 2 poly (ADP-ribose) polymerase (PARP) inhibitors for men with metastatic castration-resistant prostate cancer who have certain genetic mutations, marking the first approvals of this newer drug class in prostate cancer.
Online prostate cancer videos earn poor grade for accuracyMay 18th 2020
Misinformation about prostate cancer is rampant online and significantly impacts patient care, study authors said at an American Urological Association press briefing. Researchers using machine learning have taken what they say is a first step to help vet the quality of online content.
Surveillance for small renal masses appears safe at 10 yearsMay 14th 2020
Data from a large registry showed that active surveillance for small renal masses was safe and noninferior to primary intervention at 10 years. In this video, senior author Phillip M. Pierorazio, MD, of Johns Hopkins University discusses results of the study presented as part of the AUA 2020 Virtual Experience.
Study will test targeted PCa therapies based on genomic alterationsMarch 5th 2020
Martin Gleave, MD, of the University of British Columbia in Vancouver, discusses the Genomic Umbrella Neoadjuvant Study (GUNS) trial, which uses a multi-arm, multistage adaptive design to test targeted therapies in patients with high-risk localized disease by matching neoadjuvant therapies to baseline genomic alterations.
CTC subtypes: A prognostic marker in GU cancer patients?January 22nd 2020
In a study of circulating tumor cells (CTCs) in metastatic genitourinary cancer patients, shorter survival was associated with high CTC counts at baseline and on therapy, specific CTC morphologic subtypes, PD-L1-positive CTCs, and low percent CD4 and percent CD8 T-cells. Heather Chalfin, MD, discusses the data and explains how CTCs may offer an advantage over other forms of liquid biopsy.
Pembrolizumab granted new bladder Ca indicationJanuary 14th 2020
The FDA has approved the anti-PD-1 therapy pembrolizumab (KEYTRUDA) as monotherapy for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
FDA approves enfortumab for locally advanced or metastatic urothelial CaJanuary 14th 2020
The FDA has granted accelerated approval to enfortumab vedotin-ejfv (PADCEV) for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before or after surgery or in a locally advanced or metastatic setting.
FDA approves new drug for UTI, two devices for OAB/incontinenceDecember 4th 2019
November 2019 proved to be a fruitful month for urology-specific FDA approvals, with the agency giving the green light to a new drug for complicated urinary tract infection, an implantable device for the treatment of overactive bladder/retention, and a digital product for strengthening of pelvic floor muscles and treatment of urinary incontinence in women.
State of the specialty: Slumping pay, burnout drive retirementDecember 1st 2018
More than one-fourth of urologists say they have specific plans to retire within the next 2 years. An ongoing drop in reimbursement, feeling burned out, and government mandates are the primary factors affecting when they will retire, according to the 13th annual Urology Times State of the Specialty survey.
LUGPA backs CMS plan for site-neutral pay for servicesNovember 2nd 2018
Changes in the Medicare fee schedule, including plans to pay essentially the same amount for services whether performed in a hospital provider-based department (PBD) or in individual physician offices, were hailed as “significant wins” in a Health Policy Forum at the 2018 LUGPA annual meeting in Chicago.
Sicker MIBC patients no more likely to undergo bladder sparingAugust 14th 2018
Even though patients with muscle-invasive bladder cancer and significant comorbidity are likely to benefit from bladder-sparing treatment approaches, increasing comorbidity burden appears to have no correlation with receiving such treatments.
Study appears to refute obesity paradox in kidney cancerDecember 9th 2015
In this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.
Genomic variation in IC/BPS based on bladder capacityAugust 25th 2014
Patients with interstitial cystitis/bladder pain syndrome who have low bladder capacity have a significantly different gene expression profile than both IC/BPS patients with normal bladder capacity and those without the condition, researchers reported in a recently published pilot study.